182 related articles for article (PubMed ID: 30817099)
21. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
[TBL] [Abstract][Full Text] [Related]
22. Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder.
Ward K; Citrome L
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):229-238. PubMed ID: 29258368
[TBL] [Abstract][Full Text] [Related]
23. Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Results from Two Randomized, Placebo-controlled Trials.
Sheehan DV; Gasior M; McElroy SL; Radewonuk J; Herman BK; Hudson J
Innov Clin Neurosci; 2018 Jun; 15(5-6):22-29. PubMed ID: 30013816
[No Abstract] [Full Text] [Related]
24. A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.
Childress AC; Lloyd E; Johnson SA; Gunawardhana L; Arnold V
J Child Adolesc Psychopharmacol; 2022 Mar; 32(2):98-106. PubMed ID: 35230142
[No Abstract] [Full Text] [Related]
25. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
Biederman J; Krishnan S; Zhang Y; McGough JJ; Findling RL
Clin Ther; 2007 Mar; 29(3):450-63. PubMed ID: 17577466
[TBL] [Abstract][Full Text] [Related]
26. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
[TBL] [Abstract][Full Text] [Related]
27. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.
Childress AC; Arnold V; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; Lopez FA
J Atten Disord; 2014 Feb; 18(2):123-32. PubMed ID: 22740112
[TBL] [Abstract][Full Text] [Related]
28. Effect of lisdexamfetamine on emotional network brain dysfunction in binge eating disorder.
Fleck DE; Eliassen JC; Guerdjikova AI; Mori N; Williams S; Blom TJ; Beckwith T; Tallman MJ; Adler CM; DelBello MP; Strakowski SM; McElroy SL
Psychiatry Res Neuroimaging; 2019 Apr; 286():53-59. PubMed ID: 30903953
[TBL] [Abstract][Full Text] [Related]
29. Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder.
Schneider E; Higgs S; Dourish CT
Eur Neuropsychopharmacol; 2021 Dec; 53():49-78. PubMed ID: 34461386
[TBL] [Abstract][Full Text] [Related]
30. The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study.
Schneider E; Martin E; Rotshtein P; Qureshi KL; Chamberlain SR; Spetter MS; Dourish CT; Higgs S
Transl Psychiatry; 2022 Jan; 12(1):9. PubMed ID: 35013131
[TBL] [Abstract][Full Text] [Related]
31. Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis.
Brownley KA; Berkman ND; Peat CM; Lohr KN; Cullen KE; Bann CM; Bulik CM
Ann Intern Med; 2016 Sep; 165(6):409-20. PubMed ID: 27367316
[TBL] [Abstract][Full Text] [Related]
32. Efficacy, safety, and tolerability of nivasorexant in adults with binge-eating disorder: A randomized, Phase II proof of concept trial.
McElroy SL; Coloma PM; Berger B; Guerdjikova AI; Joyce JM; Liebowitz MR; Pain S; Rabasa C
Int J Eat Disord; 2023 Nov; 56(11):2120-2130. PubMed ID: 37584285
[TBL] [Abstract][Full Text] [Related]
33. Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Banaschewski T; Johnson M; Nagy P; Otero IH; Soutullo CA; Yan B; Zuddas A; Coghill DR
CNS Drugs; 2018 May; 32(5):455-467. PubMed ID: 29790103
[TBL] [Abstract][Full Text] [Related]
34. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
35. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
[TBL] [Abstract][Full Text] [Related]
36. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.
Coghill DR; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson CS; Civil R; Dauphin M; Higgins N; Lyne A; Gasior M; Squires LA
J Am Acad Child Adolesc Psychiatry; 2014 Jun; 53(6):647-657.e1. PubMed ID: 24839883
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials.
Maneeton B; Maneeton N; Likhitsathian S; Suttajit S; Narkpongphun A; Srisurapanont M; Woottiluk P
Drug Des Devel Ther; 2015; 9():1927-36. PubMed ID: 25897203
[TBL] [Abstract][Full Text] [Related]
38. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
[TBL] [Abstract][Full Text] [Related]
39. Relationship of ADHD symptoms and global illness severity in adults treated with lisdexamfetamine dimesylate.
Weisler RH; Babcock T; Adeyi B; Brams M
Postgrad Med; 2014 Sep; 126(5):31-41. PubMed ID: 25295648
[TBL] [Abstract][Full Text] [Related]
40. Treatment With Lisdexamfetamine Dimesylate Improves Self- and Informant-Rated Executive Function Behaviors and Clinician- and Informant-Rated ADHD Symptoms in Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Study.
Weisler R; Ginsberg L; Dirks B; Deas P; Adeyi B; Adler LA
J Atten Disord; 2017 Dec; 21(14):1198-1207. PubMed ID: 24464328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
